Home › Companies › Travere Therapeutics, Inc. › 2025-2026

Travere Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Travere Therapeutics, Inc.’s Form 8-K (Item 5.07 on EDGAR). Page generated 02 October 2026.

15Reported items
293Asset managers
4,765Fund votes
2026-05-19Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Travere Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Travere Therapeutics, Inc.

These tallies are Travere Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Travere Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-05-19
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Roy D. Baynes, M.D., Ph.D.	66,479,999	--	--	9,338,149	5,290,327	Majority: yes
Elect Director: Suzanne Bruhn, Ph.D.	74,711,994	--	--	1,106,154	5,290,327	Majority: yes
Elect Director: Timothy Coughlin	73,695,965	--	--	2,122,183	5,290,327	Majority: yes
Elect Director: Eric Dube, Ph.D.	75,095,860	--	--	722,288	5,290,327	Majority: yes
Elect Director: Gary Lyons	74,208,952	--	--	1,609,196	5,290,327	Majority: yes
Elect Director: Jeffrey Meckler	73,469,263	--	--	2,348,885	5,290,327	Majority: yes
Elect Director: John A. Orwin	74,657,472	--	--	1,160,676	5,290,327	Majority: yes
Elect Director: Sandra Poole	74,551,138	--	--	1,267,010	5,290,327	Majority: yes
Elect Director: Ron Squarer	74,767,455	--	--	1,050,693	5,290,327	Majority: yes
Elect Director: Ruth Williams-Brinkley	74,764,679	--	--	1,053,469	5,290,327	Majority: yes
Proposal 2: Approval of the Company's 2018 Equity Incentive Plan, as amended The Company's stockholders approved the 2018 Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by 3,000,000	72,998,395	2,787,402	32,347	--	5,290,327	Majority: yes
Proposal 3: Approval, on an advisory basis, of the compensation of the Company's named executive officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers	73,711,670	2,073,324	33,152	--	5,290,327	Majority: yes
Proposal 5: Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of Ernst & Young LLP as the Company's independent registered public accounting firm for the fisc	80,708,265	120,699	279,509	--	--	Majority: yes

Source: Travere Therapeutics, Inc., Form 8-K — read the filing on EDGAR.

How asset managers voted at the Travere Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 293 asset managers that disclosed a Travere Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Travere Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 7 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 73,711,670AGAINST: 2,073,324

Travere Therapeutics, Inc.’s own tally for this item (“Proposal 3: Approval, on an advisory basis, of the compensation of the Company's named executive officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive offic”): 73,711,670 for, 2,073,324 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 92,992,905 outstanding shares: 79% for, 2% against (81% of the company cast a for/against vote).

The 289 asset managers below cast 99% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR 97%

FOR: 97.4%AGAINST: 1.4%ABSTAIN: 1.2%NOT VOTED: 0.0%

Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers.” at Travere Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Fidelity	22,092,134	0	0	For
Janus Henderson	18,535,475	0	0	For
Vanguard	7,394,283	5	0	For
BlackRock	6,416,394	0	0	For
State Street	4,523,004	2,880	0	For
NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST	2,977,033	0	0	For
JANUS INVESTMENT FUND	2,609,963	0	0	For
PERCEPTIVE ADVISORS LLC	2,381,160	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	2,329,445	0	0	For
Delaware/Macquarie	2,167,048	0	0	For
Invesco	1,826,160	0	0	For
T. Rowe Price	1,680,940	0	0	For
Charles Schwab	1,582,243	0	0	For
Stephens Investment Management Group LLC	1,503,064	0	0	For
Kynam Capital Management, LP	0	0	1,279,898	Abstain
ARMISTICE CAPITAL, LLC	1,034,961	0	0	For
ADAGE CAPITAL PARTNERS GP, L.L.C.	977,000	0	0	For
Nuveen	933,877	0	0	For
TIAA	901,860	0	0	For
EMERALD ADVISERS, LLC	811,843	0	0	For
MPM BioImpact LLC	765,072	0	0	For
RA CAPITAL MANAGEMENT, L.P.	746,841	0	0	For
Ensign Peak Advisors, Inc	722,788	0	0	For
Northern Trust	717,629	0	0	For
Wellington	664,150	0	0	For

Showing the 25 largest of 289 asset managers. See all 289 in the interactive database.

2. To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Combines 6 wordings of this item as funds reported it.

100% fund support · no official result

ABSTAIN 15%ONE YEAR 68%1 YEAR 15%

The 286 asset managers below cast 100% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR: 2.0%ABSTAIN: 14.9%ONE YEAR: 67.6%1 YEAR: 14.9%3 YEARS: 0.6%1.0: 0.0%THREE YEARS: 0.0%NOT VOTED: 0.0%1-YEAR: 0.0%3.0: 0.0%2 YEARS: 0.0%

Largest asset managers voting on “To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation o” at Travere Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	0	0	One Year
Janus Henderson	0	0	One Year
Kynam Capital Management, LP	0	18,064,452	Abstain
Vanguard	0	0	One Year
BlackRock	0	0	1 Year
State Street	0	0	One Year
NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST	0	0	One Year
JANUS INVESTMENT FUND	0	0	One Year
PERCEPTIVE ADVISORS LLC	2,381,160	0	For
GEODE CAPITAL MANAGEMENT, LLC	0	0	One Year
Delaware/Macquarie	0	0	One Year
Invesco	0	0	One Year
T. Rowe Price	0	0	One Year
Charles Schwab	0	0	1 Year
Stephens Investment Management Group LLC	0	0	One Year
ARMISTICE CAPITAL, LLC	0	0	1 Year
ADAGE CAPITAL PARTNERS GP, L.L.C.	0	0	One Year
Nuveen	0	0	One Year
TIAA	0	0	One Year
EMERALD ADVISERS, LLC	0	0	1 Year
MPM BioImpact LLC	0	0	1 Year
RA CAPITAL MANAGEMENT, L.P.	0	0	One Year
Ensign Peak Advisors, Inc	0	0	3 Years
Northern Trust	0	0	1 Year
Wellington	0	0	1 Year

Showing the 25 largest of 286 asset managers. See all 286 in the interactive database.

3. TO APPROVE THE COMPANY'S 2018 EQUITY INCENTIVE PLAN, AS AMENDED, TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE THEREUNDER BY 3,000,000 SHARES.

COMPENSATIONMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 72,998,395AGAINST: 2,787,402

Travere Therapeutics, Inc.’s own tally for this item (“Proposal 2: Approval of the Company's 2018 Equity Incentive Plan, as amended The Company's stockholders approved the 2018 Plan, as amended, to increase the number of shares of common stock authorized for issuance thereun”): 72,998,395 for, 2,787,402 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 92,992,905 outstanding shares: 78% for, 3% against (81% of the company cast a for/against vote).

The 89 asset managers below cast 99.5% of the shares they voted on this item FOR (37,968,568 for, 183,017 against).

FOR 99.4%

FOR: 37,968,568 (99.5%)AGAINST: 183,017 (0.5%)ABSTAIN: 10,466 (0.0%)

Largest asset managers voting on “TO APPROVE THE COMPANY'S 2018 EQUITY INCENTIVE PLAN, AS AMENDED, TO INCREASE THE NUMBER OF SHARES OF COMMON ST” at Travere Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Fidelity	11,505,154	0	For
Vanguard	6,658,332	7,606	For
BlackRock	3,474,068	0	For
State Street	2,893,924	4,426	For
JANUS INVESTMENT FUND	2,609,963	0	For
Delaware/Macquarie	2,167,048	0	For
TIAA	901,860	0	For
Charles Schwab	790,994	0	For
T. Rowe Price	636,141	0	For
RBB FUND, INC.	571,828	0	For
Eversept Partners, LP	456,374	0	For
Invesco	400,839	0	For
Principal	380,322	0	For
Waddell & Reed	363,711	0	For
Bridge Builder Trust	352,475	0	For
First Trust	266,944	0	For
DRIEHAUS MUTUAL FUNDS	249,132	0	For
IMPAX FUNDS SERIES TRUST I	225,000	0	For
Equitable	186,713	0	For
Calamos	177,188	0	For
Voya	141,212	0	For
JPMorgan	130,637	0	For
AMERICAN BEACON FUNDS	129,274	0	For
QUANTITATIVE MASTER SERIES LLC	111,828	0	For
DWS	106,037	0	For

Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.

4. To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year. ELECTION OF DIRECTORS: Eric Dube

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

99.0% Majority: yes · of votes cast

FOR 99.0%

FOR: 75,095,860WITHHELD: 722,288

Travere Therapeutics, Inc.’s own tally for this item (“Elect Director: Eric Dube, Ph.D.”): 75,095,860 for, 722,288 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 92,992,905 outstanding shares: 81% for, 0.8% withheld (82% of the company cast a for/withheld vote).

The 86 asset managers below cast 100% of the shares they voted on this item FOR (37,698,968 for, 0 against).

FOR 99.9%

FOR: 37,698,968 (100.0%)ABSTAIN: 6,196 (0.0%)

Largest asset managers voting on “To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for ” at Travere Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	11,505,154	0	For
Vanguard	6,665,937	1	For
BlackRock	3,474,068	0	For
State Street	2,898,321	29	For
JANUS INVESTMENT FUND	2,609,963	0	For
Delaware/Macquarie	2,167,048	0	For
TIAA	901,860	0	For
Charles Schwab	790,994	0	For
T. Rowe Price	636,141	0	For
RBB FUND, INC.	571,828	0	For
Invesco	400,839	0	For
Principal	380,322	0	For
Waddell & Reed	363,711	0	For
Bridge Builder Trust	352,475	0	For
First Trust	266,944	0	For
DRIEHAUS MUTUAL FUNDS	249,132	0	For
IMPAX FUNDS SERIES TRUST I	225,000	0	For
Equitable	186,713	0	For
Calamos	177,188	0	For
Voya	141,212	0	For
JPMorgan	130,637	0	For
AMERICAN BEACON FUNDS	129,274	0	For
QUANTITATIVE MASTER SERIES LLC	111,828	0	For
DWS	106,037	0	For
Hartford	104,562	0	For

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

5. To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year. ELECTION OF DIRECTORS: Gary Lyons

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 74,208,952WITHHELD: 1,609,196

Travere Therapeutics, Inc.’s own tally for this item (“Elect Director: Gary Lyons”): 74,208,952 for, 1,609,196 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 92,992,905 outstanding shares: 80% for, 2% withheld (82% of the company cast a for/withheld vote).

The 86 asset managers below cast 100% of the shares they voted on this item FOR (37,695,365 for, 0 against).

FOR 99.9%

FOR: 37,695,365 (100.0%)ABSTAIN: 9,799 (0.0%)

Largest asset managers voting on “To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for ” at Travere Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	11,505,154	0	For
Vanguard	6,662,334	3,604	For
BlackRock	3,474,068	0	For
State Street	2,898,321	29	For
JANUS INVESTMENT FUND	2,609,963	0	For
Delaware/Macquarie	2,167,048	0	For
TIAA	901,860	0	For
Charles Schwab	790,994	0	For
T. Rowe Price	636,141	0	For
RBB FUND, INC.	571,828	0	For
Invesco	400,839	0	For
Principal	380,322	0	For
Waddell & Reed	363,711	0	For
Bridge Builder Trust	352,475	0	For
First Trust	266,944	0	For
DRIEHAUS MUTUAL FUNDS	249,132	0	For
IMPAX FUNDS SERIES TRUST I	225,000	0	For
Equitable	186,713	0	For
Calamos	177,188	0	For
Voya	141,212	0	For
JPMorgan	130,637	0	For
AMERICAN BEACON FUNDS	129,274	0	For
QUANTITATIVE MASTER SERIES LLC	111,828	0	For
DWS	106,037	0	For
Hartford	104,562	0	For

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

6. To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year. ELECTION OF DIRECTORS: Jeffrey Meckler

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 73,469,263WITHHELD: 2,348,885

Travere Therapeutics, Inc.’s own tally for this item (“Elect Director: Jeffrey Meckler”): 73,469,263 for, 2,348,885 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 92,992,905 outstanding shares: 79% for, 3% withheld (82% of the company cast a for/withheld vote).

The 86 asset managers below cast 100% of the shares they voted on this item FOR (37,688,104 for, 0 against).

FOR 99.9%

FOR: 37,688,104 (100.0%)ABSTAIN: 17,060 (0.0%)

Largest asset managers voting on “To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for ” at Travere Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	11,505,154	0	For
Vanguard	6,662,333	3,605	For
BlackRock	3,474,068	0	For
State Street	2,898,234	116	For
JANUS INVESTMENT FUND	2,609,963	0	For
Delaware/Macquarie	2,167,048	0	For
TIAA	901,860	0	For
Charles Schwab	790,994	0	For
T. Rowe Price	636,141	0	For
RBB FUND, INC.	571,828	0	For
Invesco	400,839	0	For
Principal	380,322	0	For
Waddell & Reed	363,711	0	For
Bridge Builder Trust	352,475	0	For
First Trust	266,944	0	For
DRIEHAUS MUTUAL FUNDS	249,132	0	For
IMPAX FUNDS SERIES TRUST I	225,000	0	For
Equitable	186,713	0	For
Calamos	177,188	0	For
Voya	141,212	0	For
JPMorgan	130,637	0	For
AMERICAN BEACON FUNDS	129,274	0	For
QUANTITATIVE MASTER SERIES LLC	111,828	0	For
DWS	106,037	0	For
Hartford	104,562	0	For

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

7. To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year. ELECTION OF DIRECTORS: John Orwin

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 74,657,472WITHHELD: 1,160,676

Travere Therapeutics, Inc.’s own tally for this item (“Elect Director: John A. Orwin”): 74,657,472 for, 1,160,676 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 92,992,905 outstanding shares: 80% for, 1% withheld (82% of the company cast a for/withheld vote).

The 86 asset managers below cast 100% of the shares they voted on this item FOR (37,698,995 for, 0 against).

FOR 99.9%

FOR: 37,698,995 (100.0%)ABSTAIN: 6,169 (0.0%)

Largest asset managers voting on “To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for ” at Travere Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	11,505,154	0	For
Vanguard	6,665,935	3	For
BlackRock	3,474,068	0	For
State Street	2,898,350	0	For
JANUS INVESTMENT FUND	2,609,963	0	For
Delaware/Macquarie	2,167,048	0	For
TIAA	901,860	0	For
Charles Schwab	790,994	0	For
T. Rowe Price	636,141	0	For
RBB FUND, INC.	571,828	0	For
Invesco	400,839	0	For
Principal	380,322	0	For
Waddell & Reed	363,711	0	For
Bridge Builder Trust	352,475	0	For
First Trust	266,944	0	For
DRIEHAUS MUTUAL FUNDS	249,132	0	For
IMPAX FUNDS SERIES TRUST I	225,000	0	For
Equitable	186,713	0	For
Calamos	177,188	0	For
Voya	141,212	0	For
JPMorgan	130,637	0	For
AMERICAN BEACON FUNDS	129,274	0	For
QUANTITATIVE MASTER SERIES LLC	111,828	0	For
DWS	106,037	0	For
Hartford	104,562	0	For

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

8. To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year. ELECTION OF DIRECTORS: Ron Squarer

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 74,767,455WITHHELD: 1,050,693

Travere Therapeutics, Inc.’s own tally for this item (“Elect Director: Ron Squarer”): 74,767,455 for, 1,050,693 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 92,992,905 outstanding shares: 80% for, 1% withheld (82% of the company cast a for/withheld vote).

The 86 asset managers below cast 100% of the shares they voted on this item FOR (37,698,995 for, 0 against).

FOR 99.9%

FOR: 37,698,995 (100.0%)ABSTAIN: 6,169 (0.0%)

Largest asset managers voting on “To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for ” at Travere Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	11,505,154	0	For
Vanguard	6,665,935	3	For
BlackRock	3,474,068	0	For
State Street	2,898,350	0	For
JANUS INVESTMENT FUND	2,609,963	0	For
Delaware/Macquarie	2,167,048	0	For
TIAA	901,860	0	For
Charles Schwab	790,994	0	For
T. Rowe Price	636,141	0	For
RBB FUND, INC.	571,828	0	For
Invesco	400,839	0	For
Principal	380,322	0	For
Waddell & Reed	363,711	0	For
Bridge Builder Trust	352,475	0	For
First Trust	266,944	0	For
DRIEHAUS MUTUAL FUNDS	249,132	0	For
IMPAX FUNDS SERIES TRUST I	225,000	0	For
Equitable	186,713	0	For
Calamos	177,188	0	For
Voya	141,212	0	For
JPMorgan	130,637	0	For
AMERICAN BEACON FUNDS	129,274	0	For
QUANTITATIVE MASTER SERIES LLC	111,828	0	For
DWS	106,037	0	For
Hartford	104,562	0	For

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

9. To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year. ELECTION OF DIRECTORS: Roy Baynes

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%12%

FOR: 66,479,999WITHHELD: 9,338,149

Travere Therapeutics, Inc.’s own tally for this item (“Elect Director: Roy D. Baynes, M.D., Ph.D.”): 66,479,999 for, 9,338,149 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 92,992,905 outstanding shares: 71% for, 10% withheld (82% of the company cast a for/withheld vote).

The 86 asset managers below cast 100% of the shares they voted on this item FOR (33,596,111 for, 0 against).

FOR 89%11%

FOR: 33,596,111 (89.1%)ABSTAIN: 4,109,053 (10.9%)

Largest asset managers voting on “To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for ” at Travere Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	11,466,986	38,168	For
Vanguard	6,662,330	3,608	For
BlackRock	172,796	3,301,272	Abstain
State Street	2,897,540	810	For
JANUS INVESTMENT FUND	2,609,963	0	For
Delaware/Macquarie	2,167,048	0	For
TIAA	901,860	0	For
Charles Schwab	790,994	0	For
T. Rowe Price	636,141	0	For
RBB FUND, INC.	571,828	0	For
Invesco	400,839	0	For
Principal	380,322	0	For
Waddell & Reed	363,711	0	For
Bridge Builder Trust	335,413	17,062	For
First Trust	266,944	0	For
DRIEHAUS MUTUAL FUNDS	249,132	0	For
IMPAX FUNDS SERIES TRUST I	225,000	0	For
Equitable	69,530	117,183	Abstain
Calamos	177,188	0	For
Voya	0	141,212	Abstain
JPMorgan	130,637	0	For
AMERICAN BEACON FUNDS	129,274	0	For
QUANTITATIVE MASTER SERIES LLC	0	111,828	Abstain
DWS	106,037	0	For
Hartford	0	104,562	Abstain

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

10. To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year. ELECTION OF DIRECTORS: Ruth Williams-Brinkley

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 74,764,679WITHHELD: 1,053,469

Travere Therapeutics, Inc.’s own tally for this item (“Elect Director: Ruth Williams-Brinkley”): 74,764,679 for, 1,053,469 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 92,992,905 outstanding shares: 80% for, 1% withheld (82% of the company cast a for/withheld vote).

The 86 asset managers below cast 100% of the shares they voted on this item FOR (37,698,995 for, 0 against).

FOR 99.9%

FOR: 37,698,995 (100.0%)ABSTAIN: 6,169 (0.0%)

Largest asset managers voting on “To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for ” at Travere Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	11,505,154	0	For
Vanguard	6,665,935	3	For
BlackRock	3,474,068	0	For
State Street	2,898,350	0	For
JANUS INVESTMENT FUND	2,609,963	0	For
Delaware/Macquarie	2,167,048	0	For
TIAA	901,860	0	For
Charles Schwab	790,994	0	For
T. Rowe Price	636,141	0	For
RBB FUND, INC.	571,828	0	For
Invesco	400,839	0	For
Principal	380,322	0	For
Waddell & Reed	363,711	0	For
Bridge Builder Trust	352,475	0	For
First Trust	266,944	0	For
DRIEHAUS MUTUAL FUNDS	249,132	0	For
IMPAX FUNDS SERIES TRUST I	225,000	0	For
Equitable	186,713	0	For
Calamos	177,188	0	For
Voya	141,212	0	For
JPMorgan	130,637	0	For
AMERICAN BEACON FUNDS	129,274	0	For
QUANTITATIVE MASTER SERIES LLC	111,828	0	For
DWS	106,037	0	For
Hartford	104,562	0	For

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

11. To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year. ELECTION OF DIRECTORS: Sandra Poole

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 74,551,138WITHHELD: 1,267,010

Travere Therapeutics, Inc.’s own tally for this item (“Elect Director: Sandra Poole”): 74,551,138 for, 1,267,010 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 92,992,905 outstanding shares: 80% for, 1% withheld (82% of the company cast a for/withheld vote).

The 86 asset managers below cast 100% of the shares they voted on this item FOR (37,692,298 for, 0 against).

FOR 99.9%

FOR: 37,692,298 (100.0%)ABSTAIN: 12,866 (0.0%)

Largest asset managers voting on “To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for ” at Travere Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	11,505,154	0	For
Vanguard	6,665,935	3	For
BlackRock	3,474,068	0	For
State Street	2,898,350	0	For
JANUS INVESTMENT FUND	2,609,963	0	For
Delaware/Macquarie	2,167,048	0	For
TIAA	901,860	0	For
Charles Schwab	790,994	0	For
T. Rowe Price	636,141	0	For
RBB FUND, INC.	571,828	0	For
Invesco	400,839	0	For
Principal	380,322	0	For
Waddell & Reed	363,711	0	For
Bridge Builder Trust	352,475	0	For
First Trust	266,944	0	For
DRIEHAUS MUTUAL FUNDS	249,132	0	For
IMPAX FUNDS SERIES TRUST I	225,000	0	For
Equitable	186,713	0	For
Calamos	177,188	0	For
Voya	141,212	0	For
JPMorgan	130,637	0	For
AMERICAN BEACON FUNDS	129,274	0	For
QUANTITATIVE MASTER SERIES LLC	111,828	0	For
DWS	106,037	0	For
Hartford	104,562	0	For

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

12. To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year. ELECTION OF DIRECTORS: Suzanne Bruhn

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 74,711,994WITHHELD: 1,106,154

Travere Therapeutics, Inc.’s own tally for this item (“Elect Director: Suzanne Bruhn, Ph.D.”): 74,711,994 for, 1,106,154 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 92,992,905 outstanding shares: 80% for, 1% withheld (82% of the company cast a for/withheld vote).

The 86 asset managers below cast 100% of the shares they voted on this item FOR (37,698,995 for, 0 against).

FOR 99.9%

FOR: 37,698,995 (100.0%)ABSTAIN: 6,169 (0.0%)

Largest asset managers voting on “To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for ” at Travere Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	11,505,154	0	For
Vanguard	6,665,935	3	For
BlackRock	3,474,068	0	For
State Street	2,898,350	0	For
JANUS INVESTMENT FUND	2,609,963	0	For
Delaware/Macquarie	2,167,048	0	For
TIAA	901,860	0	For
Charles Schwab	790,994	0	For
T. Rowe Price	636,141	0	For
RBB FUND, INC.	571,828	0	For
Invesco	400,839	0	For
Principal	380,322	0	For
Waddell & Reed	363,711	0	For
Bridge Builder Trust	352,475	0	For
First Trust	266,944	0	For
DRIEHAUS MUTUAL FUNDS	249,132	0	For
IMPAX FUNDS SERIES TRUST I	225,000	0	For
Equitable	186,713	0	For
Calamos	177,188	0	For
Voya	141,212	0	For
JPMorgan	130,637	0	For
AMERICAN BEACON FUNDS	129,274	0	For
QUANTITATIVE MASTER SERIES LLC	111,828	0	For
DWS	106,037	0	For
Hartford	104,562	0	For

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

13. To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year. ELECTION OF DIRECTORS: Timothy Coughlin

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 73,695,965WITHHELD: 2,122,183

Travere Therapeutics, Inc.’s own tally for this item (“Elect Director: Timothy Coughlin”): 73,695,965 for, 2,122,183 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 92,992,905 outstanding shares: 79% for, 2% withheld (82% of the company cast a for/withheld vote).

The 86 asset managers below cast 100% of the shares they voted on this item FOR (37,474,803 for, 0 against).

FOR 99.3%

FOR: 37,474,803 (99.4%)ABSTAIN: 230,361 (0.6%)

Largest asset managers voting on “To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for ” at Travere Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	11,505,154	0	For
Vanguard	6,665,933	5	For
BlackRock	3,474,068	0	For
State Street	2,898,234	116	For
JANUS INVESTMENT FUND	2,609,963	0	For
Delaware/Macquarie	2,167,048	0	For
TIAA	901,860	0	For
Charles Schwab	790,994	0	For
T. Rowe Price	636,141	0	For
RBB FUND, INC.	571,828	0	For
Invesco	400,839	0	For
Principal	380,322	0	For
Waddell & Reed	363,711	0	For
Bridge Builder Trust	352,475	0	For
First Trust	266,944	0	For
DRIEHAUS MUTUAL FUNDS	249,132	0	For
IMPAX FUNDS SERIES TRUST I	225,000	0	For
Equitable	186,713	0	For
Calamos	177,188	0	For
Voya	141,212	0	For
JPMorgan	130,637	0	For
AMERICAN BEACON FUNDS	129,274	0	For
QUANTITATIVE MASTER SERIES LLC	111,828	0	For
DWS	106,037	0	For
Hartford	0	104,562	Abstain

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

14. TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%

FOR: 80,708,265AGAINST: 120,699

Travere Therapeutics, Inc.’s own tally for this item (“Proposal 5: Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of Ernst & Young LLP as the Company's independent regist”): 80,708,265 for, 120,699 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 92,992,905 outstanding shares: 87% for, 0.2% against (87% of the company cast a for/against vote).

The 86 asset managers below cast 100% of the shares they voted on this item FOR (37,698,998 for, 0 against).

FOR 99.9%

FOR: 37,698,998 (100.0%)ABSTAIN: 6,166 (0.0%)

Largest asset managers voting on “TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPA” at Travere Therapeutics, Inc., 2025-2026
Asset manager	For	Vote
Fidelity	11,505,154	For
Vanguard	6,665,938	For
BlackRock	3,474,068	For
State Street	2,898,350	For
JANUS INVESTMENT FUND	2,609,963	For
Delaware/Macquarie	2,167,048	For
TIAA	901,860	For
Charles Schwab	790,994	For
T. Rowe Price	636,141	For
RBB FUND, INC.	571,828	For
Invesco	400,839	For
Principal	380,322	For
Waddell & Reed	363,711	For
Bridge Builder Trust	352,475	For
First Trust	266,944	For
DRIEHAUS MUTUAL FUNDS	249,132	For
IMPAX FUNDS SERIES TRUST I	225,000	For
Equitable	186,713	For
Calamos	177,188	For
Voya	141,212	For
JPMorgan	130,637	For
AMERICAN BEACON FUNDS	129,274	For
QUANTITATIVE MASTER SERIES LLC	111,828	For
DWS	106,037	For
Hartford	104,562	For

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

15. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

ONE YEAR 96%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (2,624 for, 0 against).

FOR: 2,624 (0.6%)ONE YEAR: 456,374 (96.2%)1 YEAR: 15,390 (3.2%)

Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at Travere Therapeutics, Inc., 2025-2026
Asset manager	For	Vote
Eversept Partners, LP	0	One Year
Vinva Investment Management Ltd	0	1 Year
CLEARWATER INVESTMENT TRUST	2,624	For

Largest Travere Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Travere Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 92,992,905 shares outstanding at the time of that meeting.

Top Travere Therapeutics, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Fidelity	23.76%
2	Janus Henderson	19.93%
3	Vanguard	7.95%
4	BlackRock	6.90%
5	State Street	4.87%
6	NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST	3.20%
7	JANUS INVESTMENT FUND	2.81%
8	PERCEPTIVE ADVISORS LLC	2.56%
9	GEODE CAPITAL MANAGEMENT, LLC	2.50%
10	Delaware/Macquarie	2.33%

Reported Travere Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Travere Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
FMR (Fidelity)	11.79%	13F
Janus Henderson Investors	11.40%	DEF14A
Fidelity Management & Research Company (FMR) LLC	11.36%	DEF14A
BlackRock	8.38%	13F
The Vanguard Group	6.45%	DEF14A
BANK OF AMERICA CORP /DE/	5.85%	13G
Perceptive Advisors LLC	4.60%	13G
STATE STREET CORPORATION	4.58%	13G
Geode Capital	2.55%	13F
Renaissance Technologies	2.11%	13F

Percentages above are of 92,992,905 shares outstanding, as reported by Travere Therapeutics, Inc. on its Form 10-Q dated 2026-04-30 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Travere Therapeutics, Inc.’s 10-Q dated 2026-04-30. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Travere Therapeutics, Inc.'s shareholder meeting held 2026-05-19, in the 2025-2026 proxy season, 293 asset managers reported how they voted in their SEC Form N-PX filings, covering 4,765 separate fund positions. Their filings are grouped here into 15 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers. — FOR was 97% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Travere Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission (filing date not recorded for this item).

Travere Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).